Collection of Blood Specimens for Circulating Tumor Cell Analysis
This trial is active, not recruiting.
|Conditions||breast cancer, prostate cancer, colorectal cancer|
|Collaborator||Commonwealth Hematology-Oncology, P.C.|
|Start date||September 2013|
|End date||February 2016|
|Trial size||55 participants|
|Trial identifier||NCT01943500, T30-0001|
Objective: To test the sensitivity of a proprietary novel filtration device designed to capture and concentrate circulating tumor cells (CTCs).
|Observational model||case control|
Confirmed patients with breast, prostate, or colorectal cancer (OR) subjects with no prior history of cancer
The number of circulating tumor cells (CTCs) per milliliter of whole blood. Reported unit of measure will be the number of CTCs/milliliter.
time frame: Analysis will be performed within 96 hours following blood sample collection
Male or female participants at least 18 years old.
Inclusion Criteria: - Age > 18 years of age - Written informed consent obtained - Confirmed diagnosis of stage 2-4 breast, prostate, or colorectal cancer, (OR) no prior history of cancer - Stage 2-4 treatment naive, metastatic, secondary, and recurrent cancer patients - Able to undergo blood collection prior to initiation of chemotherapy treatment, (OR) able to provide blood sample if subject is a non-cancer control subject Exclusion Criteria: - Patients unable to understand the research protocol and/or provide informed consent. - Patients with known immunodeficiency, or pregnancy.
|Official title||Collection of Blood Specimens for Circulating Tumor Cell Analysis|
|Principal investigator||Pedro M Sanz-Altamira, MD, PhD|
Call for more information